Skip to main content

Cel Sci Corp

CVM
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000725363

In the last 90 days, Cel Sci Corp insiders filed 1 open-market purchase and 0 sales; 40 institutions reported holding it in 13F filings for Q2 2026, worth $2.08M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Cel Sci Corp changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of CVM: Q2 2021 compared with Q3 2021
MeasureQ2 2021Of which not filed for Q3 2021Q3 2021Change
Holders1171110−6
Shares13.9M27.2K16.1M+2.22M (+16.0%)
Value$121.1M$236.0K$177.3M+$56.4M (+46.7%)

1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (13)

Institutions that held Cel Sci Corp at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to CVM in Q3 2021
InstitutionSharesValue% of portfolio
Citadel Advisors LLC169,397$1.86M0.00%
Two Sigma Investments, LP122,763$1.35M0.00%
Two Sigma Advisers, LP64,200$706.0K0.00%
Susquehanna Fundamental Investments, LLC21,800$240.0K0.00%
Marshall Wace, LLP20,883$230.0K0.00%
SG Americas Securities, LLC14,684$161.0K0.00%
E Fund Management Co., Ltd.11,782$129.0K0.01%
Lincoln National Corp10,245$113.0K0.00%
Northwestern Mutual Wealth Management Co10,000$110.0K0.00%
Herold Advisors, Inc.1,500$16.0K0.01%
Kings Point Capital Management1,000$11.0K0.00%
Quadrant Capital Group LLC50$1.00K0.00%
Parallel Advisors, LLC126$1.00K0.00%

Sold out (19)

Institutions that held Cel Sci Corp at the end of Q2 2021 and filed for Q3 2021 without it.

Not filed for Q3 2021 yet (1)

Institutions that held Cel Sci Corp at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CVM in Q2 2021 that haven't filed for Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
M Holdings Securities, Inc.27,226$236.0K